TEXT messages to improve MEDication adherence and Secondary prevention (TEXTMEDS) after acute coronary syndrome: A randomised clinical trial protocol

Clara K Chow; Aravinda Thiagalingam; Karla Santo; Cindy Kok; Jay Thakkar; Sandrine Stepien; Laurent Billot; Stephen Jan; Rohina Joshi; Graham S Hillis; David Brieger; Derek P Chew; Karin Rådholm; John J Atherton; Ravinay Bhindi; Nicholas Collins; Steven Coverdale; Christian Hamilton-Craig; Nadarajah Kangaharan; Andrew Maiorana; Michelle McGrady; Pratap Shetty; Peter Thompson; Anthony Rogers; Julie Redfern

doi:10.1136/bmjopen-2017-019463

TEXT messages to improve MEDication adherence and Secondary prevention (TEXTMEDS) after acute coronary syndrome: A randomised clinical trial protocol

Clara K Chow^*
, Aravinda Thiagalingam
, Karla Santo
, Cindy Kok
, Jay Thakkar
, Sandrine Stepien
, Laurent Billot
, Stephen Jan
, Rohina Joshi
, Graham S Hillis
, David Brieger
, Derek P Chew
, Karin Rådholm
, John J Atherton
, Ravinay Bhindi
, Nicholas Collins
, Steven Coverdale
, Christian Hamilton-Craig
, Nadarajah Kangaharan
, Andrew Maiorana

Michelle McGrady, Pratap Shetty, Peter Thompson, Anthony Rogers, Julie Redfern

^*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

22 Citations (Scopus)

24 Downloads (Pure)

Abstract

BACKGROUND: Identifying simple, low-cost and scalable means of supporting lifestyle change and medication adherence for patients following a cardiovascular (CV) event is important.

OBJECTIVE: The TEXTMEDS (TEXT messages to improve MEDication adherence and Secondary prevention) study aims to investigate whether a cardiac education and support programme sent via mobile phone text message improves medication adherence and risk factor levels in patients following an acute coronary syndrome (ACS).

STUDY DESIGN: A single-blind, multicentre, randomised clinical trial of 1400 patients after an ACS with 12 months follow-up. The intervention group will receive multiple weekly text messages that provide information, motivation, support to adhere to medications, quit smoking (if relevant) and recommendations for healthy diet and exercise. The primary endpoint is the percentage of patients who are adherent to cardioprotective medications and the key secondary outcomes are mean systolic blood pressure (BP) and low-density lipoprotein cholesterol. Secondary outcomes will also include total cholesterol, mean diastolic BP, the percentage of participants who are adherent to each cardioprotective medication class, the percentage of participants who achieve target levels of CV risk factors, major vascular events, hospital readmissions and all-cause mortality. The study will be augmented by formal economic and process evaluations to assess acceptability, utility and cost-effectiveness.

SUMMARY: The study will provide multicentre randomised trial evidence of the effects of a text message-based programme on cardioprotective medication adherence and levels of CV risk factors.

ETHICS AND DISSEMINATION: Primary ethics approval was received from Western Sydney Local Health District Human Research Ethics Committee (HREC2012/12/4.1 (3648) AU RED HREC/13/WMEAD/15). Results will be disseminated via peer-reviewed publications and presentations at international conferences.

TRIAL REGISTRATION NUMBER: ACTRN12613000793718; Pre-results.

Original language	English
Article number	e019463
Pages (from-to)	1-9
Number of pages	9
Journal	BMJ Open
Volume	8
Issue number	1
DOIs	https://doi.org/10.1136/bmjopen-2017-019463
Publication status	Published - 27 Jan 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1136/bmjopen-2017-019463Licence: CC BY-NC

TEXT messages to improve MEDication adherence and Secondary prevention (TEXTMEDS) after acute coronary syndrome A randomised clinical trial protocolFinal published version, 842 KBLicence: CC BY-NC

Cite this

Chow, C. K., Thiagalingam, A., Santo, K., Kok, C., Thakkar, J., Stepien, S., Billot, L., Jan, S., Joshi, R., Hillis, G. S., Brieger, D., Chew, D. P., Rådholm, K., Atherton, J. J., Bhindi, R., Collins, N., Coverdale, S., Hamilton-Craig, C., Kangaharan, N., ... Redfern, J. (2018). TEXT messages to improve MEDication adherence and Secondary prevention (TEXTMEDS) after acute coronary syndrome: A randomised clinical trial protocol. BMJ Open, 8(1), 1-9. Article e019463. https://doi.org/10.1136/bmjopen-2017-019463

@article{bd04676695dd4db587d290694b584254,

title = "TEXT messages to improve MEDication adherence and Secondary prevention (TEXTMEDS) after acute coronary syndrome: A randomised clinical trial protocol",

abstract = "BACKGROUND: Identifying simple, low-cost and scalable means of supporting lifestyle change and medication adherence for patients following a cardiovascular (CV) event is important.OBJECTIVE: The TEXTMEDS (TEXT messages to improve MEDication adherence and Secondary prevention) study aims to investigate whether a cardiac education and support programme sent via mobile phone text message improves medication adherence and risk factor levels in patients following an acute coronary syndrome (ACS).STUDY DESIGN: A single-blind, multicentre, randomised clinical trial of 1400 patients after an ACS with 12 months follow-up. The intervention group will receive multiple weekly text messages that provide information, motivation, support to adhere to medications, quit smoking (if relevant) and recommendations for healthy diet and exercise. The primary endpoint is the percentage of patients who are adherent to cardioprotective medications and the key secondary outcomes are mean systolic blood pressure (BP) and low-density lipoprotein cholesterol. Secondary outcomes will also include total cholesterol, mean diastolic BP, the percentage of participants who are adherent to each cardioprotective medication class, the percentage of participants who achieve target levels of CV risk factors, major vascular events, hospital readmissions and all-cause mortality. The study will be augmented by formal economic and process evaluations to assess acceptability, utility and cost-effectiveness.SUMMARY: The study will provide multicentre randomised trial evidence of the effects of a text message-based programme on cardioprotective medication adherence and levels of CV risk factors.ETHICS AND DISSEMINATION: Primary ethics approval was received from Western Sydney Local Health District Human Research Ethics Committee (HREC2012/12/4.1 (3648) AU RED HREC/13/WMEAD/15). Results will be disseminated via peer-reviewed publications and presentations at international conferences.TRIAL REGISTRATION NUMBER: ACTRN12613000793718; Pre-results.",

author = "Chow, \{Clara K\} and Aravinda Thiagalingam and Karla Santo and Cindy Kok and Jay Thakkar and Sandrine Stepien and Laurent Billot and Stephen Jan and Rohina Joshi and Hillis, \{Graham S\} and David Brieger and Chew, \{Derek P\} and Karin R{\aa}dholm and Atherton, \{John J\} and Ravinay Bhindi and Nicholas Collins and Steven Coverdale and Christian Hamilton-Craig and Nadarajah Kangaharan and Andrew Maiorana and Michelle McGrady and Pratap Shetty and Peter Thompson and Anthony Rogers and Julie Redfern",

note = "{\textcopyright} Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.",

year = "2018",

month = jan,

day = "27",

doi = "10.1136/bmjopen-2017-019463",

language = "English",

volume = "8",

pages = "1--9",

journal = "BMJ Open",

issn = "2044-6055",

publisher = "BMJ Publishing Group",

number = "1",

}

Chow, CK, Thiagalingam, A, Santo, K, Kok, C, Thakkar, J, Stepien, S, Billot, L, Jan, S, Joshi, R, Hillis, GS, Brieger, D, Chew, DP, Rådholm, K, Atherton, JJ, Bhindi, R, Collins, N, Coverdale, S, Hamilton-Craig, C, Kangaharan, N, Maiorana, A, McGrady, M, Shetty, P, Thompson, P, Rogers, A & Redfern, J 2018, 'TEXT messages to improve MEDication adherence and Secondary prevention (TEXTMEDS) after acute coronary syndrome: A randomised clinical trial protocol', BMJ Open, vol. 8, no. 1, e019463, pp. 1-9. https://doi.org/10.1136/bmjopen-2017-019463

TY - JOUR

T1 - TEXT messages to improve MEDication adherence and Secondary prevention (TEXTMEDS) after acute coronary syndrome: A randomised clinical trial protocol

AU - Chow, Clara K

AU - Thiagalingam, Aravinda

AU - Santo, Karla

AU - Kok, Cindy

AU - Thakkar, Jay

AU - Stepien, Sandrine

AU - Billot, Laurent

AU - Jan, Stephen

AU - Joshi, Rohina

AU - Hillis, Graham S

AU - Brieger, David

AU - Chew, Derek P

AU - Rådholm, Karin

AU - Atherton, John J

AU - Bhindi, Ravinay

AU - Collins, Nicholas

AU - Coverdale, Steven

AU - Hamilton-Craig, Christian

AU - Kangaharan, Nadarajah

AU - Maiorana, Andrew

AU - McGrady, Michelle

AU - Shetty, Pratap

AU - Thompson, Peter

AU - Rogers, Anthony

AU - Redfern, Julie

PY - 2018/1/27

Y1 - 2018/1/27

N2 - BACKGROUND: Identifying simple, low-cost and scalable means of supporting lifestyle change and medication adherence for patients following a cardiovascular (CV) event is important.OBJECTIVE: The TEXTMEDS (TEXT messages to improve MEDication adherence and Secondary prevention) study aims to investigate whether a cardiac education and support programme sent via mobile phone text message improves medication adherence and risk factor levels in patients following an acute coronary syndrome (ACS).STUDY DESIGN: A single-blind, multicentre, randomised clinical trial of 1400 patients after an ACS with 12 months follow-up. The intervention group will receive multiple weekly text messages that provide information, motivation, support to adhere to medications, quit smoking (if relevant) and recommendations for healthy diet and exercise. The primary endpoint is the percentage of patients who are adherent to cardioprotective medications and the key secondary outcomes are mean systolic blood pressure (BP) and low-density lipoprotein cholesterol. Secondary outcomes will also include total cholesterol, mean diastolic BP, the percentage of participants who are adherent to each cardioprotective medication class, the percentage of participants who achieve target levels of CV risk factors, major vascular events, hospital readmissions and all-cause mortality. The study will be augmented by formal economic and process evaluations to assess acceptability, utility and cost-effectiveness.SUMMARY: The study will provide multicentre randomised trial evidence of the effects of a text message-based programme on cardioprotective medication adherence and levels of CV risk factors.ETHICS AND DISSEMINATION: Primary ethics approval was received from Western Sydney Local Health District Human Research Ethics Committee (HREC2012/12/4.1 (3648) AU RED HREC/13/WMEAD/15). Results will be disseminated via peer-reviewed publications and presentations at international conferences.TRIAL REGISTRATION NUMBER: ACTRN12613000793718; Pre-results.

AB - BACKGROUND: Identifying simple, low-cost and scalable means of supporting lifestyle change and medication adherence for patients following a cardiovascular (CV) event is important.OBJECTIVE: The TEXTMEDS (TEXT messages to improve MEDication adherence and Secondary prevention) study aims to investigate whether a cardiac education and support programme sent via mobile phone text message improves medication adherence and risk factor levels in patients following an acute coronary syndrome (ACS).STUDY DESIGN: A single-blind, multicentre, randomised clinical trial of 1400 patients after an ACS with 12 months follow-up. The intervention group will receive multiple weekly text messages that provide information, motivation, support to adhere to medications, quit smoking (if relevant) and recommendations for healthy diet and exercise. The primary endpoint is the percentage of patients who are adherent to cardioprotective medications and the key secondary outcomes are mean systolic blood pressure (BP) and low-density lipoprotein cholesterol. Secondary outcomes will also include total cholesterol, mean diastolic BP, the percentage of participants who are adherent to each cardioprotective medication class, the percentage of participants who achieve target levels of CV risk factors, major vascular events, hospital readmissions and all-cause mortality. The study will be augmented by formal economic and process evaluations to assess acceptability, utility and cost-effectiveness.SUMMARY: The study will provide multicentre randomised trial evidence of the effects of a text message-based programme on cardioprotective medication adherence and levels of CV risk factors.ETHICS AND DISSEMINATION: Primary ethics approval was received from Western Sydney Local Health District Human Research Ethics Committee (HREC2012/12/4.1 (3648) AU RED HREC/13/WMEAD/15). Results will be disseminated via peer-reviewed publications and presentations at international conferences.TRIAL REGISTRATION NUMBER: ACTRN12613000793718; Pre-results.

UR - https://www.scopus.com/pages/publications/85051974512

U2 - 10.1136/bmjopen-2017-019463

DO - 10.1136/bmjopen-2017-019463

M3 - Article

C2 - 29374674

SN - 2044-6055

VL - 8

SP - 1

EP - 9

JO - BMJ Open

JF - BMJ Open

IS - 1

M1 - e019463

ER -

TEXT messages to improve MEDication adherence and Secondary prevention (TEXTMEDS) after acute coronary syndrome: A randomised clinical trial protocol

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this